You heard insulin costs $35 now. Congress passed it, the ads say it, your cousin on Medicare pays it. Then the pharmacy counter quotes you $147 and you're left wondering which part was a lie. None of it was; there are just four different $35 doors, each with its own eligibility, and the counter doesn't tell you which one you're standing in front of. This guide is the decode: which cap or program covers you, why the price on your receipt is still high, and the exact move that fixes it.
On Medicare: the $35 cap is the law
The Inflation Reduction Act capped every covered insulin at $35 for a month's supply, and the deductible doesn't apply. That covers Part D insulin you pick up at the pharmacy and Part B insulin used with a covered pump, which got the same $35 monthly cap. If you're on Medicare and a covered insulin rings up above $35, that's a processing error: ask the pharmacy to rerun the claim, and call your plan if it persists. The broader Medicare picture (CGMs, supplies, the works) lives in the Medicare diabetes coverage guide.
The fine print that catches people: the cap applies to insulins on your plan's formulary. If your endocrinologist has you on an insulin your Part D plan doesn't list, there's no $35 price to cap, and the fix is a formulary exception: your prescriber attests that the covered alternatives would work less well or harm you, and the plan must decide within 72 hours (24 if expedited). Once granted, the insulin is covered and the cap kicks in. The exception-versus-appeal guide walks the whole instrument.
Commercial insurance or no insurance: the manufacturer $35 programs
- Lilly (Humalog, Lyumjev, Basaglar, Humulin): the Insulin Value Program caps any Lilly insulin at $35 a month. Answer two questions online, download the card immediately, show your phone at the counter. Works with commercial insurance or none (Medicare and Medicaid excluded); 1-800-545-5979 for questions.
- Novo Nordisk (NovoLog, Fiasp, Novolin, Levemir, Tresiba): MyInsulinRx is $35 for a monthly supply, up to 3 vials or 2 packs of pens. Enroll online or text ENROLL to 24177; commercially insured and uninsured both qualify.
- Sanofi (Lantus, Toujeo, Admelog, Apidra): the Insulins Valyou Savings Program covers every U.S. patient with a valid prescription, regardless of insurance type, at $35 for a 30-day supply of any combination of Sanofi insulins, as of January 2026. Enroll through Sanofi Patient Connection or 1-888-847-4877.
Two habits make these stick. Re-enroll every January: the cards expire each calendar year, and the first expensive January fill is how most people discover that. And if your pharmacy claims the card "didn't go through," ask them to run it as secondary to your insurance, then call the program's number from the pharmacy counter; the makers staff those lines to fix exactly this.
State copay caps: why your friend pays $25 and you don't
Many states have passed insulin copay-cap laws, most landing between $25 and $100 for a month's supply on commercial plans. The catch is jurisdiction: state insurance law only reaches state-regulated plans, mostly individual and small-group coverage. Self-funded employer plans, where the employer pays claims itself and the insurer only administers, are governed by federal ERISA law and are exempt from state caps. Most big-company plans are self-funded. So your friend at a small firm pays a capped $25 while your Fortune 500 plan charges $120 for the same pen, legally. To find out which you have, ask HR or call the member line and ask, "Is this plan fully insured or self-funded?" If you're self-funded, skip the state law and go straight to the manufacturer program above.
The decode: which bucket are you in?
- Medicare (any Part D or a Part B pump): you're capped at $35 for covered insulins already. Over $35 at the counter means a claim error (make them rerun it) or an off-formulary insulin (file a formulary exception).
- Commercial insurance, state-regulated plan, in a cap state: your copay is capped by law. Verify with your state insurance department's site, and stack a manufacturer card if the cap still beats it.
- Commercial insurance, self-funded employer plan: state caps don't reach you. Enroll in your maker's $35 program today; it takes minutes.
- Uninsured: Lilly, Novo, and Sanofi all cover you at about $35 a month. Sanofi's program is open regardless of insurance status; the emergency guide has the same-day mechanics.
- Any bucket, still stuck: the prescription cost playbook and the full diabetes money map cover the remaining levers, from 90-day fills to patient assistance programs.
How Kite handles this
Kite does the decode with you. Text it which insulin you take and how you're covered, and it walks your bucket conversationally: whether the Medicare cap should already apply, which manufacturer program matches your insulin, and the fully-insured-or-self-funded question to ask HR. If a formulary rejection letter shows up, photograph it and Kite decodes it and drafts the appeal letter as a PDF (Pro). Then it sets the reminders that keep this solved: refill nudges and the January re-enrollment ping before the card expires. Text Kite to start.